FDA Clears AI Tool to Predict Breast Cancer Recurrence Earlier

A newly FDA-cleared AI tool targets early-stage, hormone-receptor-positive breast cancer, aiming to tell patients sooner whether their cancer is likely to return.

An AI tool designed to predict breast cancer recurrence has received FDA clearance, according to a report shared by @ABC. The tool focuses on early-stage, hormone-receptor-positive, HER2-negative cases — one of the most common breast cancer subtypes — and is intended to help doctors answer, earlier than current methods allow, whether a patient's cancer is likely to come back.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae.

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Proin pharetra nonummy pede. Mauris et orci. Aenean nec lorem. In porttitor. Donec laoreet nonummy augue. Suspendisse dui purus, scelerisque at, vulputate vitae, pretium mattis, nunc. Mauris eget neque at sem venenatis eleifend. Ut nonummy. Fusce aliquet pede non pede. Suspendisse dapibus lorem pellentesque magna integer malesuada.

Unlock the full briefing

Get every story in today's briefing, the full archive, and the daily AI intelligence brief.

All stories today

Full archive

Daily brief